Navigation Links
Omeros Corporation Reports Second Quarter 2013 Financial Results
Date:8/9/2013

SEATTLE, Aug. 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the second quarter of 2013.

Financial ResultsTotal operating expenses for the quarter ended June 30, 2013 were $13.3 million and included non-cash expenses of $2.1 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $9.8 million, which included non-cash rent and stock-based compensation expenses of $569,000.

The increase in total operating expenses for the quarter ended June 30, 2013 is primarily due to expenses related to advancing our MASP-2 program toward the clinic, the non-cash rent expense and stock-based compensation discussed above, preparing the NDA and MAA for OMS302, the planned commercial launch of OMS302 in 2014, and conducting our Phase 1 clinical program evaluating OMS824. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of our OMS302 Phase 3 clinical program in January 2013 and the completion of our first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended June 30, 2013 was $140,000 compared to $1.5 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended June 30, 2013, O
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
2. Omeros Submits New Drug Application to U.S. FDA for OMS302
3. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
4. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
5. Omeros Corporation Reports First Quarter 2013 Financial Results
6. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
7. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
8. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
9. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
10. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
11. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... 12 Novartis Pharma AG has entered into an agreement ... (iloperidone), a new oral medication that is approved by the ... of adults with schizophrenia. Novartis plans to launch Fanapt ... part of the agreement with Vanda Pharmaceuticals Inc., Novartis will ...
... Conn., Oct. 12 VION PHARMACEUTICALS, INC. (OTC ... investment banking firm Merriman Curhan Ford & Co. to assist ... of a restructuring of the Company and its debt and ... may also consider financing options. , As previously reported, the ...
Cached Medicine Technology:Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 8Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 2Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 3
(Date:8/29/2015)... ... August 29, 2015 , ... ... inventors from Miller Place, N.Y. "I specialize in manual therapy, and my invention ... it can be used for additional muscle dysfunction throughout the body." , They ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 , ... ... unofficial end of summer (which astronomically, officially ends on September 22nd this year). For ... summer-induced cyber security hangovers linger on which could prove far more costly than a ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... company to freely market and sell Arterosil and Arterosil HP, and that all ... LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States District ...
(Date:8/28/2015)... ... , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn recently ... for, they are unable to pass the initial drug test and therefore unable to ... order to be able to hire long-term, skilled talent. (1) Will Wesch, Director of ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3
... offers easy answers for plan benefits, health tools, ... gabfest about health,insurance benefits. Members logging onto myRegence.com ... provides quick answers to benefit,questions, and more., ... needs,and improving their ability to navigate the rich ...
... nears the Gulf Coast, evacuating Texans are urged to,spare ... Safe and Well,Web site., WASHINGTON, Sept. 11 ... or early Saturday morning,affecting areas of Texas and Louisiana. ... its message to residents is urgent: listen to the,directions ...
... study found that HIV care providers in rural Indiana ... referral system surrounding issues of HIV and substance abuse. ... offer quality care to their patients. , "The findings ... care system and our inability to link people easily ...
... 11 The New Jersey,Hospital Association today called for ... a for-profit company., "There is far too much ... have,this process proceed with key information shielded from the ... residents are rightfully,concerned about the high cost of health ...
... ANGELES, Sept. 11 Operation Smile, a worldwide,children,s medical ... children and young adults, will honor Mario Lopez, American ... Annual Smile Gala, September,18, 2008 at the Beverly Hilton. ... and Mark Burnett Family. "E! News" host Giuliana Rancic,emcees ...
... Heritage Month Work to ... ALEXANDRIA, Va., Sept. 11 To celebrate the beginning ... the,Hispanic/Latino American population who have, or are at risk ... the Abbott Fund, is,introducing its new Adult Prevention Toolkit ...
Cached Medicine News:Health News:Regence's Online 'Live Help' Gets Members Chatting 2Health News:American Red Cross Urges, 'Prepare for Ike' 2Health News:American Red Cross Urges, 'Prepare for Ike' 3Health News:New study on rural HIV care has economic and health implications 2Health News:NJHA: Public Deserves Full Disclosure of Horizon Conversion Plan 2Health News:Operation Smile to Honor Mario Lopez, American Idol: 'Idol Gives Back,' Roma Downey & Mark Burnett Family and Vicky Mense at Smile Gala in Los Angeles 2Health News:American Diabetes Association Announces New Latino Diabetes Toolkit 2Health News:American Diabetes Association Announces New Latino Diabetes Toolkit 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: